Crowdonomics
WatchlistPortfolio
Bionectech, Inc

Reg CF · Common Stock · Dec 2025

WithdrawnReg CFCommon Equity
via StartEngine · last checked Sep 28, 2026
Raised
$0 / $1.2M max
0% of ceiling
Investors
—
—
Post-money valuation
$7M
pre-money + amount raised

Financials disclosed in this offering

FY2023–FY2024 · hover for source
$0
−$52K
FY2023
$0
−$76K
FY2024
RevenueNet income
Metric
FY2023 reviewed
FY2024 reviewed
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$52,150
-$75,874
Taxes paid
$0
$0
Balance sheet
Cash
$0
$22,816
Accounts receivable
$0
$0
Total assets
$1,500
$66,643
Short-term debt
$11,500
$14,000
Long-term debt
$0
$0
Total liabilities
$11,500
$14,000
Other
Headcount
—
1

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Feb 9, 2026
    • Deadline May 8, 2026 → Apr 30, 2026closing early

    “Campaign end date April 30 2026”

    Form C/A on EDGAR ↗
  2. Jan 27, 2026
    • Deadline Mar 9, 2026 → May 8, 2026

    “Extending Campaign to May 8 2026”

    Form C/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.

Deal terms

Pre-money$7M
Post-money$7M
Price / share$3.00
Shares offered6,666

Offering details

Target$19,998
Max$1,234,998
Min investment—
OpenedDec 9, 2025
DeadlineApr 30, 2026
ClosedMay 7, 2026
Days active149

Links & provenance

SEC filing
Source: SEC EDGAR
0002100124-25-000002
Last synced Sep 28, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.